Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CNTA

CNTA - Centessa Pharmaceuticals Limited Stock Price, Fair Value and News

10.18USD+0.25 (+2.52%)Market Closed

Market Summary

CNTA
USD10.18+0.25
Market Closed
2.52%

CNTA Stock Price

View Fullscreen

CNTA RSI Chart

CNTA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-8.31

Price/Sales (Trailing)

167.93

EV/EBITDA

-7.27

Price/Free Cashflow

-7.68

CNTA Price/Sales (Trailing)

CNTA Profitability

EBT Margin

-2388.28%

Return on Equity

-64.33%

Return on Assets

-42.18%

Free Cashflow Yield

-13.02%

CNTA Fundamentals

CNTA Revenue

Revenue (TTM)

6.9M

CNTA Earnings

Earnings (TTM)

-138.4M

Earnings Growth (Yr)

24.98%

Earnings Growth (Qtr)

-3.28%

Breaking Down CNTA Revenue

Last 7 days

15.7%

Last 30 days

15.8%

Last 90 days

-5.3%

Trailing 12 Months

87.1%

How does CNTA drawdown profile look like?

CNTA Financial Health

Current Ratio

10.37

Debt/Equity

0.36

Debt/Cashflow

-1.95

CNTA Investor Care

Shares Dilution (1Y)

18.78%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230006.9M
20220000

Tracking the Latest Insider Buys and Sells of Centessa Pharmaceuticals Limited

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 31, 2024
bush tia l
sold (taxes)
-72,534
11.3
-6,419
chief technology & quality ofc
Mar 31, 2024
hussain iqbal j
sold (taxes)
-84,976
11.3
-7,520
general counsel
Mar 31, 2024
saha saurabh
sold (taxes)
-409,772
11.3
-36,263
chief executive officer
Mar 31, 2024
chao david m
sold (taxes)
-117,350
11.3
-10,385
chief administrative officer
Mar 31, 2024
weinhoff gregory m
sold (taxes)
-132,685
11.3
-11,742
chief financial officer
Mar 25, 2024
anderson karen m.
acquired
177,252
3.93892
45,000
chief people officer
Mar 25, 2024
anderson karen m.
sold
-607,960
11.8835
-51,160
chief people officer
Feb 01, 2024
rotman harris
acquired
-
-
37,500
svp regulatory affairs
Feb 01, 2024
rotman harris
sold (taxes)
-33,644
8.19
-4,108
svp regulatory affairs
Feb 01, 2024
rotman harris
sold
-34,574
8.1027
-4,267
svp regulatory affairs

1–10 of 50

Which funds bought or sold CNTA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
4,192,300
4,192,300
0.02%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
69.17
71,232
122,232
0.02%
May 17, 2024
Artal Group S.A.
added
39.51
7,901,250
15,961,200
0.41%
May 15, 2024
ACUTA CAPITAL PARTNERS, LLC
sold off
-100
-303,578
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
added
107
575,160
869,919
-%
May 15, 2024
5AM Venture Management, LLC
new
-
14,068,500
14,068,500
3.15%
May 15, 2024
PRELUDE CAPITAL MANAGEMENT, LLC
new
-
780,932
780,932
0.04%
May 15, 2024
Schonfeld Strategic Advisors LLC
sold off
-100
-100,526
-
-%
May 15, 2024
Octagon Capital Advisors LP
unchanged
-
6,880,730
23,279,100
2.79%
May 15, 2024
BARCLAYS PLC
sold off
-100
-51,000
-
-%

1–10 of 48

Are Funds Buying or Selling CNTA?

Are funds buying CNTA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CNTA
No. of Funds

Unveiling Centessa Pharmaceuticals Limited's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ecor1 capital, llc
5.8%
5,618,779
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
4.7%
4,624,752
SC 13G/A
Feb 09, 2023
janus henderson group plc
2.2%
2,114,519
SC 13G/A
Jan 31, 2023
medicxi growth i lp
4.2%
3,936,970
SC 13G/A
Nov 23, 2022
ecor1 capital, llc
5.5%
5,232,279
SC 13G
Jun 16, 2022
biotechnology value fund l p
4.0%
3,734,708
SC 13G
Feb 14, 2022
index ventures life vi (jersey) l.p.
10.9%
9,812,368
SC 13G
Feb 11, 2022
janus henderson group plc
6.4%
5,743,397
SC 13G
Feb 08, 2022
medicxi growth i lp
4.4%
3,936,970
SC 13G

Recent SEC filings of Centessa Pharmaceuticals Limited

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K
Current Report
May 21, 2024
DEFA14A
DEFA14A
May 13, 2024
10-Q
Quarterly Report
May 13, 2024
8-K
Current Report
May 09, 2024
ARS
ARS
May 09, 2024
DEF 14A
DEF 14A
Apr 26, 2024
PRE 14A
PRE 14A
Apr 25, 2024
424B5
Prospectus Filed
Apr 24, 2024
8-K
Current Report
Apr 23, 2024
424B5
Prospectus Filed

Peers (Alternatives to Centessa Pharmaceuticals Limited)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Centessa Pharmaceuticals Limited News

Latest updates
MarketBeat13 hours ago
MarketBeat13 Jun 202409:22 pm
Defense World13 Jun 202410:33 am

Centessa Pharmaceuticals Limited Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42022Q4
  S&GA Expenses-10.6%12,315,00013,768,000
EBITDA Margin-Infinity%-24.14-
Interest Expenses16.7%2,570,0002,202,500
Income Taxes274.0%1,155,500-664,000
Earnings Before Taxes18.6%-35,693,000-43,837,000
EBT Margin-Infinity%-25.70-
Net Income14.7%-36,837,000-43,173,000
Net Income Margin-Infinity%-22.05-
Free Cashflow40.5%-31,078,000-52,216,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-8.9%328360377393404444479521582630612644-
  Current Assets-9.7%28431533235038443847751958162961264411.00
    Cash Equivalents-7.7%1181281711452603944454845445955796147.00
  Net PPE-8.4%1.001.001.001.001.001.001.001.000.000.000.000.00-
Liabilities-8.9%11312411811611110810610110213863.0058.009.00
  Current Liabilities-30.3%27.0039.0035.0034.0030.0038.0038.0034.0027.0025.0029.0024.009.00
  Long Term Debt1.5%77.0076.0074.0073.0072.0070.0068.0067.0075.0076.00---
    LT Debt, Non Current1.5%77.0076.0074.0073.0072.0070.0068.0067.0075.0076.00---
Shareholder's Equity-8.9%215236259277293336373420480492549586-
  Retained Earnings-5.1%-790-752-716-677-652-601-558-504-440-385-324-284-9.22
  Additional Paid-In Capital1.7%1,004987974953946939933926920876871867-
Shares Outstanding1.7%10099.0098.0095.0095.0095.0094.0092.0091.0090.0070.0064.00-
Float----311---241---1,073-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q42020Q32020Q22019Q4
Cashflow From Operations-20.1%-37,286-31,050-37,392-44,062-47,838-51,564-39,088-59,877-50,017-56,427-33,170-33,877-11,635--3,281-1,895--
  Share Based Compensation9.7%8,1547,4307,5597,2137,1906,6177,0275,6035,7184,7584,1333,2292,731-91.0092.00--
Cashflow From Investing191.7%16,762-18,27548,706-71,099-86,336-446-16.00-229-240-64.00-48.00-14963,517-----
Cashflow From Financing65.0%10,4936,36114,74412.00-89.0022470.0074.0074,429-1,992345,821241,889-1,28577.00--
  Buy Backs-------------12.00-----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CNTA Income Statement

2024-03-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 22,652$ 32,826
General and administrative13,43816,051
Loss from operations(36,090)(48,877)
Interest income2,5912,531
Interest expense(2,529)(2,345)
Other (expense) income, net(1,537)(1,346)
Loss before income taxes(37,565)(50,037)
Income tax expense481677
Net loss(38,046)(50,714)
Other comprehensive (loss) income:  
Foreign currency translation adjustment(25)898
Unrealized gain on available for sale securities, net of tax1550
Other comprehensive income130898
Total comprehensive loss$ (37,916)$ (49,816)
Net loss per ordinary share - basic (in dollars per share)$ (0.38)$ (0.53)
Net loss per ordinary share - diluted (in dollars per share)$ (0.38)$ (0.53)
Weighted average ordinary shares outstanding - basic (in shares)99,887,72094,937,904
Weighted average ordinary shares outstanding - diluted (in shares)99,887,72094,937,904

CNTA Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 118,218$ 128,030
Short-term investments111,959128,519
Tax incentive receivable36,29237,818
Prepaid expenses and other current assets18,00720,725
Total current assets284,476315,092
Property and equipment, net9521,039
Operating lease right-of-use assets11,69411,914
Deferred tax asset29,16629,647
Other, net1,8832,554
Total assets328,171360,246
Current liabilities:  
Accounts payable7,49911,815
Accrued expenses and other current liabilities19,93627,570
Total current liabilities27,43539,385
Long term debt76,80075,700
Operating lease liabilities8,7448,888
Other liabilities2929
Total liabilities113,008124,002
Commitments and contingencies (Note 6)
Shareholders’ equity:  
Ordinary shares: £0.002 nominal value: 152,500 shares authorized, 100,481,993 issued and outstanding at March 31, 2024: 152,500,000 shares authorized, 98,775 issued and outstanding at December 31, 2023277273
Additional paid-in capital1,004,254987,423
Accumulated other comprehensive loss1,6231,493
Accumulated deficit(790,991)(752,945)
Total shareholders’ equity215,163236,244
Total liabilities and shareholders' equity$ 328,171$ 360,246
CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
 CEO
 WEBSITEcentessa.com
 INDUSTRYBiotechnology
 EMPLOYEES64

Centessa Pharmaceuticals Limited Frequently Asked Questions


What is the ticker symbol for Centessa Pharmaceuticals Limited? What does CNTA stand for in stocks?

CNTA is the stock ticker symbol of Centessa Pharmaceuticals Limited. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Centessa Pharmaceuticals Limited (CNTA)?

As of Fri Jun 14 2024, market cap of Centessa Pharmaceuticals Limited is 1.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CNTA stock?

You can check CNTA's fair value in chart for subscribers.

What is the fair value of CNTA stock?

You can check CNTA's fair value in chart for subscribers. The fair value of Centessa Pharmaceuticals Limited is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Centessa Pharmaceuticals Limited is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CNTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Centessa Pharmaceuticals Limited a good stock to buy?

The fair value guage provides a quick view whether CNTA is over valued or under valued. Whether Centessa Pharmaceuticals Limited is cheap or expensive depends on the assumptions which impact Centessa Pharmaceuticals Limited's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNTA.

What is Centessa Pharmaceuticals Limited's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, CNTA's PE ratio (Price to Earnings) is -8.31 and Price to Sales (PS) ratio is 167.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CNTA PE ratio will change depending on the future growth rate expectations of investors.